Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs ARCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 57.7 HOLD), While ARCT Leads 3–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: DMAC 2 – 3 ARCT (1 Tie) Matrix Metrics: DMAC 5 – 5 ARCT

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Arcturus Therapeutics Holdings Inc. (ARCT) on higher Unified Composite conviction (46.3/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARCT wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ARCT at $8.43 (2.5x Forward P/E, -311.2% operating margin).

  • Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -311.2% operating margin) and revenue trajectory (+0.0% vs. +6.7% YoY).
  • Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ARCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs ARCT
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.39
-4.55% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.72β · 97% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24
ARCT NASDAQ
Arcturus Therapeutics Holdings Inc. Common Stock
Pharmaceutical Preparations
$8.43
+0.84% 1D
Market Cap $241.0M
TTM Revenue $31M
Forward P/E 2.5x
Beta / 30D Vol 2.01β · 127% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 39
RSI-14: 39.1 · SMA20: $10.11 · SMA50: $12.28

6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 3 ARCT)

Columns: Metric · DMAC · ARCT
1. Valuation Multiples ARCT
Forward P/E N/M 2.5x
Trailing P/E N/M 2.5x
PEG Ratio N/M N/M
EV / Revenue N/M 2.6x
2. Growth & Scale ARCT
Revenue Growth (YoY) +0.0% +6.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $31M
Market Cap $503.1M $241.0M
3. Profitability & Quality DMAC
Gross Margin N/A N/A
Operating Margin 0.0% -311.2%
Net Profit Margin 0.0% -285.9%
Return on Equity (ROE) -114.6% -44.4%
4. Balance Sheet & Cash Flow ARCT
Cash Generation (TTM) -$32M -$62M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $163M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 106.3% (14th %ile) 96.3% (7th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (5) vs ARCT (5)
Institutional Metric DMAC ARCT Criterion Row Edge
Market Capitalization
Scale
$503.1M $241.0M Larger Scale DMAC
Trailing P/E Ratio
Valuation
N/M 2.5x Lower Multiple ARCT
Forward P/E Ratio
Valuation
N/M 2.5x Lower Multiple ARCT
Revenue Growth (YoY)
Growth
+0.0% +6.7% Higher Growth ARCT
Operating Margin (TTM)
Profitability
0.0% -311.2% Higher Margin DMAC
Net Profit Margin
Profitability
0.0% -285.9% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-114.6% -44.4% Higher ROE ARCT
52-Week Range Position
Momentum
55% ($5–$11) 24% ($6–$18) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.72β · 97% Vol 2.01β · 127% Vol Lower Realized Risk DMAC
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 57.7 / 100 (HOLD) Higher Composite ARCT
Trailing 12M Revenue (USD)
Operating Scale
N/A $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$62M ($163M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +29.3 pp
DMAC: +10.83% · ARCT: -18.47%
3M Horizon DMAC +24.25 pp
DMAC: +26.93% · ARCT: +2.68%
6M Horizon DMAC +27.8 pp
DMAC: +47.71% · ARCT: +19.91%
1Y Horizon DMAC +46.31 pp
DMAC: +54.8% · ARCT: +8.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue ARCT Revenue DMAC Op. Margin ARCT Op. Margin Margin Leader
FY2018 $0M $20M -1352.2% -138.5% ARCT
FY2019 N/A $20M N/A -122.7% ARCT
FY2020 N/A $10M N/A -749.8% ARCT
FY2021 N/A $10M N/A -1641.3% ARCT
FY2022 N/A $210M N/A 5.9% ARCT
FY2023 N/A $170M N/A -46.9% ARCT
FY2024 N/A $150M N/A -62.8% ARCT
FY2025 N/A $80M N/A -93.0% ARCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARCT BREAKDOWN
42d in phase · OBV DISTRIBUTION
Current IV 96.3%
IV Percentile 7th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARCT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $241.0M market capitalization and -311.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs ARCT Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Arcturus Therapeutics Holdings Inc. (ARCT) on higher Unified Composite conviction (46.3/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARCT wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ARCT at $8.43 (2.5x Forward P/E, -311.2% operating margin). Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -311.2% operating margin) and revenue trajectory (+0.0% vs. +6.7% YoY). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ARCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARCT leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARCT at +6.7% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (N/A gross margin, -311.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while ARCT shifted +300.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARCT.

ARCT screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARCT trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus ARCT (-44.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.72β · 97% Vol realized risk). By comparison, ARCT carries 96.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.